Lossos I S, Levy R
Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA 94305-5306, USA.
Blood. 2000 Feb 15;95(4):1400-5.
The BCL-6 proto-oncogene is involved in the genesis of non-Hodgkin lymphoma (NHL). Rearrangements due to chromosomal translocations and somatic mutations of the 5' noncoding regulatory region of the BCL-6 gene are potential mechanisms for altering its expression in NHL. To further elucidate the nature of the somatic mutations in the regulatory region of this gene, we have studied 10 healthy donors and 11 NHL biopsy samples by extensive molecular cloning and sequencing. In addition, we analyzed the BCL-6 genes of tumor and nontumor cells from 2 of the cases. The germ line sequence of this region was defined, which differs in 7 positions from that previously reported. In addition, 1 polymorphic variation at position 397(G or C) was identified. Deletions, insertions, and repeated substitution mutations were detected among the molecular isolates in 8 tumor specimens, with a mutational incidence ranging from 1.3 x 10(-3) to 1.3 x 10(-2)/bp (base pair). A total of 20 distinct substitution mutations, 1 insertion and 3 deletions were observed. One of these deletion mutations and 2 of the substitutions were observed in more than 1 tumor specimen from different individuals. In 3 tumor samples, identical mutations affecting both alleles were observed. These findings suggest the presence of mutational hot spots and hot specific events, a finding supported by our compilation of previously published data. In 6 samples, the nucleotide sequences showed evidence of intraclonal heterogeneity, consistent with a stepwise ongoing mutational process affecting the BCL-6 gene in the tumor cells. These mutations accumulating in the regulatory region of the BCL-6 gene could play a role in lymphoma progression and in the transformation of follicular lymphomas to more aggressive large cell lymphomas. (Blood. 2000;95:1400-1405)
BCL-6原癌基因参与非霍奇金淋巴瘤(NHL)的发生。BCL-6基因5'非编码调控区因染色体易位和体细胞突变而发生的重排是改变其在NHL中表达的潜在机制。为了进一步阐明该基因调控区体细胞突变的性质,我们通过广泛的分子克隆和测序研究了10名健康供体和11份NHL活检样本。此外,我们分析了其中2例病例的肿瘤细胞和非肿瘤细胞的BCL-6基因。确定了该区域的种系序列,其在7个位置与先前报道的序列不同。此外,在397位(G或C)鉴定出1个多态性变异。在8个肿瘤标本的分子分离物中检测到缺失、插入和重复替代突变,突变发生率为1.3×10^(-3)至1.3×10^(-2)/bp(碱基对)。共观察到20个不同的替代突变、1个插入和3个缺失。在来自不同个体的多个肿瘤标本中观察到其中1个缺失突变和2个替代突变。在3个肿瘤样本中,观察到影响两个等位基因的相同突变。这些发现提示存在突变热点和热点特异性事件,我们对先前发表数据的汇编支持了这一发现。在6个样本中,核苷酸序列显示出克隆内异质性的证据,这与影响肿瘤细胞中BCL-6基因的逐步进行性突变过程一致。这些在BCL-6基因调控区积累的突变可能在淋巴瘤进展以及滤泡性淋巴瘤向更具侵袭性的大细胞淋巴瘤转化中起作用。(《血液》。2000年;95:1400 - 1405)